NewPharmExec · 26 Oct 2026 · Collaborations & pilots
Bristol Myers Squibb gets neuroscience rights to Pathos AI's Foundry platform
Pathos AI, Bristol Myers Squibb and Tempus AI agreed multi-year collaborations on data and agentic AI for Alzheimer's and other neurological diseases. BMS gets access to the Pathos Foundry platform across its R&D and three-year exclusive rights in neuroscience; Pathos licenses a Tempus dataset for $55 million over five years. BMS also led the Pathos $237 million Series E.
Why it matters: Combining a commercial deal with a lead investment ties a pharma company closely to a startup's platform roadmap.